

Corporate Action Notice

September 21, 2018

Ratio Change and Stock Distribution

Kajima Corporation

DR CUSIP: 483111209/ DR ISIN: US4831112093

DR Ticker Symbol: KAJMY

Ratio (DS: Underlying Shares): 1:10

Please be advised that Kajima Corporation has announced a one (1) for two (2) reverse stock split on its Common shares in the local market effective October 1, 2018. As a result, BNY Mellon will change the ratio on the Kajima Corporation DR program. The ratio change will occur immediately after the reverse stock split resulting in a 400% DS distribution (4 additional DSs for each 1 DS held).

BNY Mellon will attempt to sell any fractional DSs and distribute the cash proceeds to DR holders.

Please note: A ratio change may impact the fees payable by DR investors.

BNY Mellon's books will be closed for issuances and cancellations from the close of business September 28, 2018 and anticipate opening the books on October 8, 2018.

BNY MELLON HAS ESTABLISHED THE FOLLOWING DATES FOR THIS CORPORATE ACTION:

DR Record Date:	October 2, 2018
DR Payable Date:	October 3, 2018
DR Effective Date:	October 3, 2018
DS Distribution Rate:	400% Distribution
Issuance Fee:	\$0.00
Old Ratio:	1 DS: 10 Ordinary shares
New Ratio:	1 DS: 1 Ordinary share

First day of trading under the new ratio is expected to be October 4, 2018

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

NEW YORK & LONDON

adrdesk@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and /or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf. Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.



BNY MELLON